Navigation Links
Introgen Reports Updated Phase 2 Advexin Data Correlating Improved,Survival, Tumor Responses and Predictive p53 Biomarker

of molecular and clinical biomarkers can predict the patients who are most likely to respond to ADVEXIN treatment.

About ADVEXIN

ADVEXIN p53 therapy is a targeted molecular therapy with broad applicability in a wide range of tumor types and clinical settings because it targets one of the most fundamental and common molecular defects, abnormal p53 tumor suppressor function, associated with cancer initiation, progression and treatment resistance. ADVEXIN has demonstrated increased survival and tumor growth control in recurrent head and neck cancer patients. ADVEXIN has demonstrated clinical activity in a number of solid tumor types in multiple phase 1, 2 and 3 clinical trials conducted worldwide.

Introgen's clinical collaborators included John Nemunaitis, M.D., Medical Director, Mary Crowley Medical Research Center, Gary Clayman, M.D., Department of Otolayngology, M.D. Anderson Cancer Center, Carol Bier-Laning, M.D., Clinical Assistant Professor, Loyola University Medical Center, Heikki Minn, M.D., Ph.D., Department of Oncology and Radiotherapy, Turku University Hospital, D. Van Echo, M.D., Director, HarborView Cancer Center, George Yoo, M.D., Vice-Chair, Department of Otolaryngology-Head and Neck Surgery and Oncology, Wayne State University, Kerstin Menander, PhD, M.D., Introgen's vice president of Clinical Development and W. Jarrard Goodwin M.D., Director, University of Miami Hospital & Sylvester Comprehensive Cancer Clinics.

About Introgen

Introgen Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. Introgen is developing molecular therapeutics, immunotherapies, vaccines and nano-particle tumor suppressor therapies to treat a wide range of cancers using tumor suppressors, cytokines and genes. Introgen maintains integrated research, development, manufacturing, clinical and regulatory departm
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241 in Patients With Advanced Solid Tumors
2. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
3. Introgen and Clinical Collaborators to Report New Results with Advanced-Stage Cancer Therapies at Upcoming Medical Meetings
4. Preclinical Studies Identify Novel Approach for Enhancing the Anticancer Activity of Introgens INGN 241
5. Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference
6. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
7. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
10. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
11. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
Post Your Comments:
(Date:10/13/2008)...acet Solutions, Inc. today,announced the completio...IDE Pilot Study. The results show a 78% reduction ...80% reduction in Visual Analog Scores (VAS) for,sy...or Facet Solutions,added, "We are very pleased wi...monstrate significant pain relief but the safety o...
(Date:10/12/2008)...gned for more uniform drug ...Oct. 12 /- Boston,Scientifi...hensive data from,the TAXUS ATLAS clinical program...ingle-arm, historically controlled trials, which e... Stent System in a variety of,lesions and patient ...
(Date:10/10/2008).../-,XTENT, Inc. (Nasdaq: XT...-term follow-up data from the CUSTOM I, II and III...esearch Foundation,s (CRF) twentieth annual,Transc...in Washington, DC.,The CUSTOM clinical trials are ...fety and efficacy of the Custom NX(R) drug eluting...
(Date:10/10/2008)...h Kogenate FS Reduces the,Risk of Joint Damage and...Joint Damage, BERKELEY, Calif., Oct. 10 /PRNewswi...he U.S. Food and Drug Administration (FDA) has,app...hemophilic Factor,(Recombinant) to reduce the freq...amage in patients aged 0-16 years with severe hemo...
Breaking Medicine Technology:Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 2Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 3Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 4Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 5Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 6XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week 2FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 2FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 3FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 4FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 5Wyeth Announces Executive Promotions 7304 1Wyeth Announces Executive Promotions 7304 2Wyeth Announces Executive Promotions 7304 3Wyeth Announces Executive Promotions 7304 4Wyeth Announces Executive Promotions 7304 5Wild Blueberries Shown to Fight Oxidative Stress 7299 1Wild Blueberries Shown to Fight Oxidative Stress 7299 2Experts Agree That One Case Is Too Many 3B Tackle Tough Issue of Anesthesia Awareness 7294 1Experts Agree That One Case Is Too Many 3B Tackle Tough Issue of Anesthesia Awareness 7294 2Experts Agree That One Case Is Too Many 3B Tackle Tough Issue of Anesthesia Awareness 7294 3Experts Agree That One Case Is Too Many 3B Tackle Tough Issue of Anesthesia Awareness 7294 4Women with AIDS face cervical cancer threat 1402 1Women with AIDS face cervical cancer threat 1402 2
(Date:10/13/2008)...eading Content Rights Management System, Supports... Content Spend, WEST CHESTER, Pa., Oct. 13 /PRNew...ding global pharmaceutical manufacturer has integr...primary platform for the,secure distribution, data...cs for their new product video content. Imperium i...
(Date:10/13/2008)...swire/ -- The National Coalition for,Quality Color...ncerns over,the National CT Colonography Study pub...Medicine. The evidence must be closely evaluated, ...y is not without significant,potential risks. The ...py,remains the "Gold Standard" for colorectal canc...
(Date:10/13/2008)...blem in daily life, survey shows, PORTLAND, Ore.,...three-quarters of people living with psoriasis say...e, according to a National Psoriasis,Foundation 20...viduals with psoriasis and psoriatic arthritis,als...ly lives, shapes their,feelings about themselves a...
(Date:10/13/2008)...swire/ -- During the Pri-Med New York,conference a...are providers,took a 20-question quiz prepared by ...n Somerset, NJ. The quiz tested basic knowledge of..., EMR software, and healthcare,administration., T... The average number,of correct answers was only 7....
Breaking Medicine News(10 mins):Health News:Global Pharma Integrates Imperium(TM) to Support Launch Content ROI Initiatives! 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 3Health News:National Psoriasis Foundation Releases 2008 Study Results 2Health News:MTBC Practice Management Quiz Sends Message to Doctors: There is Real Room for Improvement or a Need to Outsource 2
...bird flu alert Friday after a wild bird found in a...ian flu virus//. Officials confirmed Thursday tha...eway Bay had indicated it was suspected to have di...Further confirmatory tests are being conducted, bu...
...from west Midlands, UK, will be dishing out 7000 p...t up for sale a magic cream supposed// to cure ski...s found to contain Clobetasol Propionate, a prescr...eat severe cases of childhood eczema. Official sou...
...ity of California, San Diego physicists and neuros...rk of blood vessels// in the brain that makes it v...origin of the puzzling damage to the brain’s gray ...especially among the elderly. In the study, publis...
...ent of men treated with a combination of radiation... for prostate cancer are cured of their disease 15... study released today in the International Journal...the official journal of ASTRO. This study was con...
Other Medicine News:Health News:Bottleneck in Blood Supply Makes Brain Vulnerable to Strokes 2Health News:Bottleneck in Blood Supply Makes Brain Vulnerable to Strokes 3
Ideal for biocompatibility testing at various temperatures, this chamber provides continuous circulation of air through a clean heating unit to maintain a constant internal temperature up to 140F. Tr
This free-standing work station safely ventilates fumes upwards, away from the work surface. Optional Exhaust Purification System features bonded charcoal filters that remove organic chemical vapors
This fume hood is the same as model Scienceware H50000-0003, but includes a flat internal baffle across the rear of the shell. The baffle slopes forward, leaving space beneath for air flow to sweep t
... is an economical unit designed for small faciliti...s are needed. Excellent for use in schools, junior...-piece shell molded of chemical resistant polyethy.... A clear acrylic panel slides on a track featurin...
Medicine Products: